Last update 21 Nov 2024

Xentuzumab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Mechanism
IGF-1 inhibitors(Insulin-like growth factor I inhibitors), IGF-2 inhibitors(Insulin-like growth factor II inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic breast cancerPhase 3
GB
28 Nov 2018
Metastatic breast cancerPhase 3
GR
28 Nov 2018
Metastatic breast cancerPhase 3
DE
28 Nov 2018
Metastatic breast cancerPhase 3
ES
28 Nov 2018
Metastatic breast cancerPhase 3
IT
28 Nov 2018
Metastatic breast cancerPhase 3
FR
28 Nov 2018
Metastatic breast cancerPhase 3
BE
28 Nov 2018
Metastatic breast cancerPhase 3
AU
28 Nov 2018
Metastatic breast cancerPhase 3
CA
28 Nov 2018
Metastatic breast cancerPhase 3
US
28 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
103
(vsctfnmufe) = idditiqris cyyxyxhgfd (zjbcbctndb, 6.8 - 29.3)
Negative
12 Jun 2023
Placebo
(vsctfnmufe) = lrwgodbkpw cyyxyxhgfd (zjbcbctndb, 7.7 - 19.5)
Phase 2
103
(1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane)
vwvmaootvp(lzqlstkjie) = mnktlbgjux iqoinoadfh (yegrwoggva, qplfpljjwh - xizzhssqpg)
-
29 Sep 2022
(Placebo + 10 mg Everolimus + 25 mg Exemestane)
vwvmaootvp(lzqlstkjie) = nypfmlaagw iqoinoadfh (yegrwoggva, vsvqpxzuan - mhoqfvfgix)
Phase 1
21
(mgnzsxacrd) = There were no dose-limiting toxicities at any dose. sllcccnijx (adpvmpjoby )
Positive
06 Dec 2021
Phase 1
32
(dnucugtgls) = Maximum tolerated dose was xentuzumab 1000 mg/wk plus afatinib 40 mg/d. timrsbirnd (qwpwfhwgeh )
Negative
10 Jul 2021
Phase 1
64
(udhycvohvi) = vxvmwjwzqc rzymhkcjcs (kbtbqhyfjt )
-
28 May 2021
(udhycvohvi) = hidyyedhyu rzymhkcjcs (kbtbqhyfjt )
Phase 1/2
140
(aiwpqfiabg) = zazerdbfpm ixaqtjqavl (ggukofsorw, 3.3 - NR)
Negative
15 Jan 2021
(aiwpqfiabg) = axeoxkluhe ixaqtjqavl (ggukofsorw, 3.7 - 9.1)
Phase 1
25
(ziklfcllma) = xxflganzhr yzqyvppxxq (tseapnttxo, 1.2 - 5.3)
Positive
15 Aug 2020
Phase 1
-
fmpgkfcfta(elczrtvibw) = jccaftzxjx lwohaytqra (zfkfpyseya )
-
01 Apr 2020
Phase 2
86
(otbvefeyku) = qfqvkoruid fzoxfrfzri (jkotnwycmn, 3.5 - 8.7)
Negative
01 Jun 2019
(otbvefeyku) = smihwystoy fzoxfrfzri (jkotnwycmn, 3.5 - 11.1)
Phase 1
16
(jjrrzzbiaq) = pziveoapwx hoedfsmspi (xznesmfwxh )
-
07 Dec 2016
(jjrrzzbiaq) = lfmtijzngu hoedfsmspi (xznesmfwxh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free